Back to the future: using aminoglycosides again and how to dose them optimally.

Back to the future: using aminoglycosides again and how to dose them optimally. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Back to the future: using aminoglycosides again and how to dose them optimally. Abstract Text:

George L Drusano,Paul G Ambrose,Sujata M Bhavnani,Joseph S Bertino,Ann N Nafziger,Arnold Louie,George L Drusano,Paul G Ambrose,Sujata M Bhavnani,Joseph S Bertino,Ann N Nafziger,Arnold Louie,

Gram-negative organisms have become increasingly resistant to both beta-lactam antibiotics and fluoroquinolones. Consequently, aminoglycoside antibiotics have undergone a resurgence in use. Because of the known toxicities of aminoglycoside antibiotics, clinicians have avoided their use, unless no other alternatives were extant. Over the past 2 decades, we have learned much about the relationship between aminoglycoside exposure and the likelihood of a good clinical outcome or the occurrence of nephrotoxicity. For example, minimum inhibitory concentration values > or = 2.0 mg/L lead to unacceptably low probabilities of a good clinical outcome, and infrequent administration of doses (i.e., intervals of 24 h and longer intervals for patients with compromised renal function) plays a central role in minimizing the likelihood of toxicity. Using these new insights, we suggest ways of evaluating the dose and schedule of administration of aminoglycosides in empirical therapy to obtain the highest likelihood of an efficacious and nontoxic therapy.

Back to the future: using aminoglycosides again and how to dose them optimally. Publishing Authors By Initials

GL Drusano,PG Ambrose,SM Bhavnani,JS Bertino,AN Nafziger,A Louie,GL Drusano,PG Ambrose,SM Bhavnani,JS Bertino,AN Nafziger,A Louie,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Back to the future: using aminoglycosides again and how to dose them optimally. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical infectious diseases : an official publica

VOLUME: 45

Page Numbers: 753-60

Journal Abbreviation: Clin. Infect. Dis.

ISSN: 1537-6591

DAY: 8

MONTH: 08

YEAR: 2007

Back to the future: using aminoglycosides again and how to dose them optimally. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9203213

Back to the future: using aminoglycosides again and how to dose them optimally. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Back to the future: using aminoglycosides again and how to dose them optimally. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Back to the future: using aminoglycosides again and how to dose them optimally.

AFFILIATION: Ordway Research Institute, Albany, NY 12208, USA. gdrusano@ordwayresearch.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Back to the future: using aminoglycosides again and how to dose them optimally Related Publications

• A Rosen etymology.
• A nickel-catalyzed route to pyridines.
• A phenomenological calculus of Wiener description space.
• Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency.
• Avian influenza: Myth or mass murder?
• Back to the future: using aminoglycosides again and how to dose them optimally.
• Clinicopathologic conference: a 28-year-old woman with perioral cyanosis and low oxygen saturation.
• Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.
• Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic.
• Electric field effects on spin transport in defective metallic carbon nanotubes.
• Electron beam supercollimation in graphene superlattices.
• Encountering patient suicide: emotional responses, ethics, and implications for training programs.
• Energy gaps and stark effect in boron nitride nanoribbons.
• Essential diagnosis of abdominal emergencies in the first year of life.
• Excitonic effects in the optical spectra of graphene nanoribbons.
• Identification of quantitative trait loci controlling resistance to maize chlorotic dwarf virus.
• Integrating palliative care in severe chronic obstructive lung disease.
• Magnetic resonance imaging contrast agents in the study of development.
• Nickel-catalyzed cycloaddition of alkynes and isocyanates.
• Nickel-catalyzed cycloadditions of unsaturated hydrocarbons, aldehydes, and ketones.
• Photochromically-controlled, reversibly-activated MRI and optical contrast agent.
• Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30.
• Quasiparticle energies and band gaps in graphene nanoribbons.
• Rational use of antibiotics in the outpatient setting.
• Selectivity in nickel-catalyzed rearrangements of cyclopropylen-ynes.
• Shock tube for simulating nuclear blast durations.
• Small phonon contribution to the photoemission kink in the copper oxide superconductors.
• Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.
• The widened teardrop distance: a plain film indicator of hip joint effusion in adults.
• Velocity renormalization and carrier lifetime in graphene from the electron-phonon interaction.